AwesomeCapital

Thursday, May 7, 2026

Q1 2026 revenue was $114.5 million, essentially flat year-over-year, while adjusted net income grew 22% year-over-year.
Q1 net income totaled $45.3 million, or $0.19 per share, according to the company.
Company maintained FY 2026 revenue guidance at $530–$560 million but withdrew its long-term outlook amid increasing competition in the IG market.
Company said an internal audit found no evidence of alleged channel stuffing or undisclosed related-party transactions.

Astellas VIR-5500 collaboration closed, adding $315M near-term capital and sharing 40/60 global development costs.
Quarter-end cash was $809M, excluding $315M Astellas proceeds; runway now extends into 2H 2028.
No revenue disclosed; Q1 net loss was $126M as Vir continues heavy R&D investment.
Non-GAAP EPS of -0.85 improved 3% year over year, while revenue of -$29,000 declined 101% and missed estimates.
R&D fell to $109M from $119M YoY, mainly from lapping a $30M Alnylam payment.
VIR-5500 Phase I mCRPC data show favorable safety, low-grade CRS, and durable responses up to 12 months.
Late-line monotherapy expansion is underway; registrational Phase III for VIR-5500 targeted to begin in 2027.
Tobevibart + elebsiran achieved 88% undetectable HDV RNA at 96 weeks vs 46% on antibody alone.
Three registrational ECLIPSE HDV studies remain on track; first pivotal ECLIPSE-1 readout expected in Q4 2026.
Management positions HDV combo as potential best-in-class on viral clearance and dosing convenience vs bulevirtide/Mirum.
Q&A centered on VIR-5500 Phase III gating metrics, HDV competitive data, and HER2/EGFR T-cell engager plans.
Main concern: Clinical and regulatory execution for VIR-5500 and HDV programs in increasingly competitive markets.
Mixed quarter, driven by strengthened balance sheet and promising HDV/oncology data amid continued operating losses.

Wegovy generated 2.26 billion kroner in Q1 revenue, about double analyst expectations.
2026 constant-currency sales and operating profit guidance now implies 4%-12% decline, versus 5%-13% previously.
Wegovy reached about 200,000 weekly U.S. prescriptions by mid-April, Novo Nordisk's fastest GLP-1 launch ever.
Q1 net income was $7.61 billion, with adjusted EPS of $1.04, beating expectations.
Q1 revenue totaled $15.17 billion, above analyst sales consensus estimates.
Quarterly adjusted operating profit topped expectations, prompting a slight increase in Novo Nordisk's full-year outlook.

Company now guides 2026 system-wide same-club sales growth of about 1%, down from prior 4%–5%.
Updated 2026 outlook calls for roughly 7% revenue growth, 6% adjusted EBITDA growth and 4% adjusted EPS growth.
William Blair downgraded Planet Fitness to Market Perform from Outperform, citing slower-than-expected member sign-ups and paused Black Card price increase.
Planet Fitness paused its planned national Black Card price increase, contributing to its softer long-term growth outlook.
Outlook reduction followed slower-than-expected net member additions during the first quarter.
First-quarter EPS of $0.74 rose 25% YoY, while revenue of $337.2M increased 22% YoY.

Non-GAAP EPS $2.90 declined 13% YoY and revenue $4.7B declined 11% YoY in fiscal Q2.
Company reaffirmed full-year revenue growth outlook while updating and raising full-year adjusted EPS guidance for fiscal 2026.
Completed $2B accelerated share repurchase (ASR) program as part of capital allocation initiatives.
Reduced debt by $2.1B, lowering overall reported debt balance outstanding in the quarter.
Appointed Vitor Roque executive vice president and chief financial officer, effective May 7, following interim CFO role since December 2025.

Results topped Zacks consensus estimates for both adjusted EPS and revenue.
Company maintains 2026 guidance for EPS of $2.33–$2.47 and revenue of $14.45–$14.95 billion.

Search This Blog